Loading, please wait...
.webp&w=384&q=75){kind=logo}
Verifying...
Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
— Hippocrates
Siemens Healthineers is planning a significant exit from the American Oncology Institute (AOI). This move highlights shifting priorities in cancer care investment India and broader healthcare strategies. The company has reportedly engaged Alvarez & Marsal to manage the multi-crore deal. Currently, AOI operates 16 hospitals across India with a 500-bed capacity.
Siemens considers the AOI hospital network a non-core asset. Therefore, they aim to focus on diagnostic and therapeutic imaging instead. This potential sale aligns with global plans to streamline their portfolio. Bloomberg previously reported talks regarding a $7 billion sale of their diagnostic business. Consequently, the company is refocusing on its primary technological strengths.
The Indian cancer care market shows rapid expansion today. It reached a value of ₹1.25 lakh crore in 2024. Furthermore, analysts expect a CAGR of 10-12% over the coming years. Several private equity funds are showing interest in this acquisition. Healthcare Global Enterprises (HCG) has also been sounded out as a potential bidder. This trend demonstrates high investor confidence in specialized oncology services.
Q1: What is the estimated valuation of the American Oncology Institute deal?
The deal is expected to value the cancer care chain between ₹1,500 and ₹2,000 crore.
Q2: Who is advising Siemens on this transaction?
Investment bank Alvarez & Marsal is currently advising Siemens on the potential sale of AOI.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Link will be sent via SMS to your number.
Siemens Healthineers plans to exit the American Oncology Institute, valuing the chain at ₹2,000 crore. Explore the impacts on India's cancer care market....
3 weeks back
A review of SREBPs as key regulators of lipid synthesis in cancer and their potential as targets for precision medicine in oncology and metabolic disorders....
Today
The International Journal of Molecular Medicine retracted a miR-215 endometrial cancer study because of data duplication in Western blots and cellular image...
Today
A review of experimental rodent models for Cardiorenal Syndrome types 3 and 4, exploring the pathophysiology and limitations of current research models....
Today
A study on ballet jumps reveals how skill levels and musical tempos affect lower limb coordination variability, with implications for clinical injury preven...
Today
A study reveals that blue light exposure during sleep (LEDS) is linked to hyperglycemia and worse psychosocial outcomes in adults with Type 1 Diabetes....
Today